Thursday, October 23, 2025
INBV News
Submit Video
  • Login
  • Register
  • Home
  • Business
  • Entertainment
  • Health
  • Lifestyle
  • Politics
  • Sports
  • Technology
  • Travel
  • Weather
  • World News
  • Videos
  • More
    • Podcasts
    • Reels
    • Live Video Stream
No Result
View All Result
  • Home
  • Business
  • Entertainment
  • Health
  • Lifestyle
  • Politics
  • Sports
  • Technology
  • Travel
  • Weather
  • World News
  • Videos
  • More
    • Podcasts
    • Reels
    • Live Video Stream
No Result
View All Result
INBV News
No Result
View All Result
Home Health

FDA to come to a decision on Eisai’s and Biogen’s treatment Leqembi in July

INBV News by INBV News
March 7, 2023
in Health
394 4
0
FDA to come to a decision on Eisai’s and Biogen’s treatment Leqembi in July
548
SHARES
2.5k
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

A key step forward for Novo Nordisk’s GLP-1 pill

Why cattlemen say Trump talk of Argentine beef imports isn’t any solution

Andrew Brookes | Image Source | Getty Images

The Food and Drug Administration will make a call on whether to completely approve Eisai and Biogen‘s Alzheimer’s treatment Leqembi by July 6, the businesses announced Monday.

Leqembi is an antibody treatment that targets brain plaque related to the mind-robbing disease. It is run intravenously twice a month and slowed the progression of early Alzheimer’s disease by 27% in clinical trials. Nevertheless, it also carries risks of brain swelling and bleeding and costs $26,500 a 12 months.

Although the FDA approved Leqembi on an expedited basis in January, access to the treatment is virtually nonexistent without delay. Medicare will only cover classes of medication like Leqembi that receive expedited approval for people participating in clinical trials.

The Centers for Medicare and Medicaid Services said in January that it would offer broader coverage of Leqembi as soon because it receives full FDA approval.

Though coverage can be broader, the number of people that could access the drug will still likely be limited. Medicare has agreed to cover drugs like Leqembi once they receive full approval, but just for individuals who take part in research studies, called registries, so Medicare can collect real-world data.

It would take time to establish those studies; health-care providers and research institutes need to be recruited, and patients would also need to comply with participate. The health-care system would also need more capability to manage the diagnostic tests and infusions needed to manage the drug.

Join CNBC’s Healthy Returns on March 29, where we’ll convene a virtual gathering of CEOs, scientists, investors and innovators within the health-care space to reflect on the progress made today to reinvent the longer term of medication. Plus, we’ll have an exclusive rundown of one of the best investment opportunities in biopharma, health-tech and managed care. Learn more and register today: http://bit.ly/3DUNbRo

The Alzheimer’s Association called on CMS in December to supply unrestricted coverage of treatments like Leqembi. Members of Congress have also asked Medicare to supply broader coverage, arguing that the restrictions put individuals who live in rural communities at a drawback because providers that take part in such studies are often in greater cities.

CMS rejected the Alzheimer’s Associations request to supply unrestricted coverage last month, however the agency reiterated that it is going to cover Leqembi more broadly on the identical day it receives full FDA approval.

 “As defined in statute, to supply coverage nationally, CMS is required to look at whether a medicine is cheap and essential,” the agency said in its statement. “This standard differs from the factors utilized by the FDA to evaluate whether medications are secure and effective.”

The Alzheimer’s Association said it was “appalled” by CMS’ decision. The group estimates that 2,000 people ages 65 and older progress from mild dementia to a more advanced state of the disease daily, making them ineligible for Leqembi.

CNBC Health & Science

Read CNBC’s latest global health coverage:

“CMS’ role is to supply health care coverage. Their role shouldn’t be to face between a patient and a physician when deciding what FDA-approved treatments are appropriate. Their role shouldn’t be to single out people living with Alzheimer’s and choose that their lives, their independence and their memories usually are not essential,” said the association’s president, Joanne Pike.

Eisai’s U.S. CEO, Ivan Cheung, told CNBC last month that it’s possible Medicare could comply with provide coverage with no restrictions after Leqembi receives full approval if CMS determines there’s strong evidence to support the treatment.

“With a high level of evidence … the restrictions needs to be very limited, or perhaps even no restrictions and that’s Eisai’s position,” Cheung said. “We imagine Medicare beneficiaries must have unimpeded access, broad and straightforward access to Leqembi because the info fulfill those criteria,” Cheung said.

0

Do you believe most people eat a healthy diet?

Tags: BiogensDecideEisaisfdajulyLeqembitreatment
Share219Tweet137
INBV News

INBV News

Related Posts

edit post
A key step forward for Novo Nordisk’s GLP-1 pill

A key step forward for Novo Nordisk’s GLP-1 pill

by INBV News
October 22, 2025
0

Novo Nordisk flags flutter outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. Tom Little...

edit post
Why cattlemen say Trump talk of Argentine beef imports isn’t any solution

Why cattlemen say Trump talk of Argentine beef imports isn’t any solution

by INBV News
October 21, 2025
0

Cattle detained within the pens of the Chihuahua Regional Livestock Union , on the Jeronimo-Santa Teresa border crossing in Ciudad...

edit post
Eli Lilly Novo Nordisk stock fall on Trump GLP-1 price comments

Eli Lilly Novo Nordisk stock fall on Trump GLP-1 price comments

by INBV News
October 18, 2025
0

Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration goals to chop the...

edit post
Genentech launches direct to consumer program for flu pill Xofluza

Genentech launches direct to consumer program for flu pill Xofluza

by INBV News
October 17, 2025
0

An indication is posted in front of a Genentech office on June 12, 2025 in South San Francisco, California. Justin...

edit post
Trump pronounces efforts to expand access to IVF drugs

Trump pronounces efforts to expand access to IVF drugs

by INBV News
October 17, 2025
0

US President Donald Trump makes an announcement within the Oval Office of the White House in Washington, DC, on Oct....

Next Post
edit post
California’s Newsom slams Walgreens on abortion drugs

California's Newsom slams Walgreens on abortion drugs

edit post
Katy Perry accused of bullying ‘American Idol’ contestant: ‘Not gonna go far’

Katy Perry accused of bullying 'American Idol' contestant: 'Not gonna go far'

CATEGORIES

  • Business
  • Entertainment
  • Health
  • Lifestyle
  • Podcast
  • Politics
  • Sports
  • Technology
  • Travel
  • Videos
  • Weather
  • World News

CATEGORY

  • Business
  • Entertainment
  • Health
  • Lifestyle
  • Podcast
  • Politics
  • Sports
  • Technology
  • Travel
  • Videos
  • Weather
  • World News

SITE LINKS

  • About us
  • Contact us
  • Privacy Policy
  • Terms and Conditions
  • Disclaimer
  • DMCA

[mailpoet_form id=”1″]

  • About us
  • Contact us
  • Privacy Policy
  • Terms and Conditions
  • Disclaimer
  • DMCA

© 2022. All Right Reserved By Inbvnews.com

No Result
View All Result
  • Home
  • Business
  • Entertainment
  • Health
  • Lifestyle
  • Politics
  • Sports
  • Technology
  • Travel
  • Weather
  • World News
  • Videos
  • More
    • Podcasts
    • Reels
    • Live Video Stream

© 2022. All Right Reserved By Inbvnews.com

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist